September 7, 2017 / 11:45 AM / a year ago

Alnylam suspends bleeding disorder trial dosing after patient death

Sept 7 (Reuters) - U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient’s death.

A patient suffering from hemophilia A enrolled in a mid-stage study of the experimental treatment, fitusiran, died after developing a blood clot, Alnylam said.

French drugmaker Sanofi has an alliance with Alnylam to co-develop fitusiran. (Reporting by Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below